Bopindolol for the treatment of chronic stable angina pectoris--a clinical study of the relationship between dose and effect.

Abstract

Following a 4-week placebo period, 19 patients (12 male, average age 62.3 years) with chronic stable angina pectoris and a positive exercise test were treated with the beta-adrenoceptor antagonists bopindolol at increasing doses of 0.5, 1 and 2 mg, each being given once daily for 4 weeks. For the final 4 weeks of the study, active treatment was replaced by placebo. Maximum tolerated exercise (bicycle ergometry, performed 24 h after drug administration) increased dose-dependently from 519 +/- 59 s (baseline) to 758 +/- 95 s with 2 mg (p less than 0.001) and fell again to 508 +/- 48 s (placebo). The frequency of anginal attacks also fell dose-dependently from an average of 5.4 per week (baseline) to 0.5 with 2 mg (p less than 0.001) and rose again to 5.1 per week when active treatment was stopped.

• Authors: D Holmes, Z Fryda-Kaurimsky, K Krueger
• Journal: Cardiology (Cardiology) Vol. 77 Issue 6 Pg. 459-65 ( 1990) ISSN: 0008-6312 [Print] Switzerland
• PMID: 1981493 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Adrenergic beta-Antagonists
• Pindolol
• bopindolol

Topics

• Adrenergic beta-Antagonists (administration & dosage, adverse effects, therapeutic use)
• Aged
• Angina Pectoris (drug therapy, physiopathology)
• Dose-Response Relationship, Drug
• Electrocardiography
• Exercise Test
• Female
• Heart Rate (drug effects)
• Humans
• Male
• Middle Aged
• Pindolol (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Single-Blind Method